Feb
10
2022
On demand

TESSA technology: A new era for AAV manufacture

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

The gene therapy industry has benefitted from exciting biological advances in recent years, fuelling an ever-growing desire to ensure that more patients can benefit from these novel treatments. However, for these treatments to become widely available, manufacturing systems must keep pace with biological advances. Lack of novel manufacturing systems leave gene therapies costly, difficult to produce at scale, and subject to batch-to-batch variability.

One significant challenge comes in the manufacturing of AAV, a popular choice of viral vector to deliver new gene therapies. AAV is typically manufactured using plasmids, which are limited in efficiency and scalability. In this webinar, Dr Ryan Cawood describes how OXGENE’s plasmid free TESSA™ technology brings ‘a new era for AAV manufacture’ by manipulating the adenoviral lifecycle to provide wild type levels of adenoviral help for AAV production, without subsequent high levels of contamination.

TESSA™ vectors directly encode the genetic material required for AAV production, removing the need for plasmids to perform that function. These vectors take advantage of the dual phases of the adenoviral lifecycle to produce AAV, while limiting adenoviral contamination. Early phase adenoviral gene expression provides help for high titre AAV manufacture, while late phase gene expression, responsible for adenovirus contamination, is switched off. This increases rAAV yield, packaging efficiency and infectivity compared with plasmid based rAAV manufacture, and represses adenovirus production by 99.99999%. TESSA™ technology is fully scalable and is ideally suited for rapid and continuous production of GMP quality AAV, reducing the potential for batch-to-batch variation. Ultimately, TESSA™ technology will result in improved cost of goods and improved safety of gene therapies.

  • There are significant challenges with manufacturing AAV in a cost-effective and large-scale way using plasmid-based approaches.
  • TESSA™ vectors offer a scalable, plasmid free solution for AAV manufacturing.
  • TESSA™ vectors significantly improve AAV yields compared with other methods.
  • Large-scale GMP manufacturing is possible with TESSA™ vectors.

Dr Ryan Cawood

Chief Scientific Officer, OXGENE

Ryan founded Oxford Genetics (trading as OXGENE) in 2011, after earning a degree in genetics and a PhD in gene therapy from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™. Ryan used his background in virology to guide and grow the business through a series of strategic changes that deployed the SnapFast™ technology for cell and gene therapy discovery and manufacturing applications. He has over 20 peer reviewed papers and is the inventor on more than 100 international patent applications. In 2021, Ryan led the sale of the OXGENE to WuXi Advanced Therapies. He is currently the Chief Scientific Officer for WuXi Advanced Therapies and OXGENE.


SPEAKERS

Ryan Cawood
Chief Scientific Officer at OXGENE

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
14
Hrs
19
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
6
Hrs
19
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
22
Days
6
Hrs
19
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
20
Days
6
Hrs
19
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
13
Days
14
Hrs
19
Min
Register